Journal articles: 'Subclinical organ damage'

1

Kizer, Jorge R. "Enhancing Detection of Subclinical End-Organ Damage." Circulation 128, no. 10 (September 3, 2013): 1045–47. http://dx.doi.org/10.1161/circulationaha.113.004793.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Stavropoulos, Konstantinos, Konstantinos P. Imprialos, Michael Doumas, Vasilios G. Athyros, and Asterios Karagiannis. "Subclinical target organ damage in primary aldosteronism." Journal of Hypertension 36, no. 3 (March 2018): 701. http://dx.doi.org/10.1097/hjh.0000000000001642.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Sehestedt, Thomas, and Michael H. Olsen. "Subclinical organ damage and cardiovascular risk prediction." Blood Pressure 19, no. 3 (January 2010): 132–39. http://dx.doi.org/10.3109/08037051.2010.483054.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Tornese, F., R. Arsena, G. Geraci, F. Incalcaterra, L. Guarino, G. Cerasola, and S. Cottone. "FETUIN-A AND SUBCLINICAL ORGAN DAMAGE IN RENAL DYSFUNCTION." Journal of Hypertension 29 (June 2011): e55. http://dx.doi.org/10.1097/00004872-201106001-00138.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Olszanecka, Agnieszka, Aneta Pośnik-Urbańska, Kalina Kawecka-Jaszcz, and Danuta Czarnecka. "Subclinical organ damage in perimenopausal women with essential hypertension." Polish Archives of Internal Medicine 120, no. 10 (October 1, 2010): 390–98. http://dx.doi.org/10.20452/pamw.977.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Ayub, Ahsan, Hammad Ur Rehman Bhatti, Muhammad Farooq, Aftab Rabbani, and Muhammad Ayyaz. "Subclinical Target Damage of Organ and Creatinine Clearance in Patients with Primary Hypertension." Pakistan Journal of Medical and Health Sciences 16, no. 1 (January 30, 2022): 978–80. http://dx.doi.org/10.53350/pjmhs22161978.

Full text

Abstract:

Background: In spite of the broadly documented risk-factors of uncontrolled hypertension, this ailment is still not cured in most patients. This may be due largely to the symptomless disease nature in the initial 15-20 years, also with progressive damage to the cardio-vascular system. Therefore, the valuation of target damage of organs due to hypertension subclinically is an important procedure for diagnosis of risk-factors stratification in patients with hypertension. The aim of this study is to determine the subclinical target damage of organ among patients with primary hypertension Study Design: A prospective case-control study. Methods: A total of 120 patients were included in this study. Patients with >60 creatinine clearance rate were taken as controls and < 60 creatinine clearance rate as the case group. The 2 groups were made of equal patients 60 in each group. The Cockcroft-Gault formula was applied for determination of renal function and echocardiography was used for valuation of Left ventricular hypertrophy. Direct ophthalmoscopy was done in all patients to assess the retinal vascular changes. Urine microalbumin was evaluated from the morning spot sample. Results: 120 total patients were included in this study. There were 55 males and 65 females. 52.50 ± 8.61 years was the mean age in the control group and in the case group it was 62.20 ± 7.99 years. The incidence of left ventricular hypertrophy with CCR <60 was 23.3% and 48.3% in patients with CCR >60 (p = 0.001). The incidence of microalbuminuria in this analysis was 41.6% in the case group (p = 0.004) and it was 16.7% in the control group. Of the 120 patients in the study, 65 (54.2%) were taking medications for hypertension while 73.3% of the patients in the control group were using drugs for hypertension, the proportion of patients using antihypertensive drugs was 63.7%. Blood pressure was controlled in only 25.8% of the cases taking antihypertensive drugs Conclusions: The obtained outcomes indicate that decreased clearance of creatinine and / or the existence of microalbuminuria is indication of subclinical damage of organ and taken as a marker among individuals with essential hypertension and standard creatinine clearance, independent of BP burden and additional risk factors. Keywords: Target organ damage, primary hypertension, subclinical and creatinine clearance.

APA, Harvard, Vancouver, ISO, and other styles

7

Azevedo, O., F. Ferreira, F. Almeida, C. Ferreira, J. Guardado, M. Fernandes, I. Machado, R. Medeiros, and J. Almeida. "BLOOD PRESSURE VARIABILITY AND SUBCLINICAL TARGET ORGAN DAMAGE: PP.35.472." Journal of Hypertension 28 (June 2010): e590. http://dx.doi.org/10.1097/01.hjh.0000383809.05535.da.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Gardikioti, V., C. Vlachopoulos, D. Terentes-Printzios, E. Sigala, S. Pantou, N. Ioakeimidis, K. Aznaouridis, P. Mitropoulou, G. Christopoulou, and D. Tousoulis. "ALBUMIN-TO-CREATININE RATIO AND SUBCLINICAL ORGAN DAMAGE IN HYPERTENSIVES." Journal of Hypertension 36, Supplement 1 (June 2018): e271-e272. http://dx.doi.org/10.1097/01.hjh.0000539784.26235.51.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Handschin, Anja, Stefanie Brighenti-Zogg, Jonas Mundwiler, Stéphanie Giezendanner, Claudia Gregoriano, Benedict Martina, Peter Tschudi, Jörg D. Leuppi, Andreas Zeller, and Thomas Dieterle. "Cardiovascular risk stratification in primary care patients with arterial hypertension: Results from the Swiss Hypertension Cohort Study (HccH)." European Journal of Preventive Cardiology 26, no. 17 (June 12, 2019): 1843–51. http://dx.doi.org/10.1177/2047487319856732.

Full text

Abstract:

Aims Few data are available on cardiovascular risk stratification in primary care patients treated for arterial hypertension. This study aimed at evaluating the cardiovascular risk profile of hypertensive patients included into the Swiss Hypertension Cohort Study according to the 2013 European Society of Hypertension/European Society of Cardiology Guidelines. Methods The Swiss Hypertension Cohort Study is a prospective, observational study conducted by the Centre for Primary Health Care of the University of Basel from 2006 to 2013. Patients with a diagnosis of arterial hypertension (office blood pressure measurement ≥140/90 mmHg) were enrolled. Office blood pressure measurement, cardiovascular risk factors, subclinical organ damage, diabetes mellitus, and established cardiovascular and renal disease were recorded at baseline and at an annual interval during routine consultations by general practitioners in Switzerland. Results In total, 1003 patients were eligible for analysis (55.6% male, mean age: 64.0 ± 13.2 years). At baseline, 78.5% of patients presented with either more than three additional cardiovascular risk factors, diabetes mellitus or subclinical organ damage, while 44.4% of patients had a high or very high overall cardiovascular risk. Cardiovascular risk factors and information about diabetes mellitus, established cardiovascular disease and renal disease were recorded mostly completely, whereas substantial gaps were revealed regarding the assessment of subclinical organ damage. Conclusion The present findings demonstrate that the majority of primary care patients with arterial hypertension bear a substantial number of additional cardiovascular risk factors, subclinical and/or established organ damage. This emphasizes the need for continuous cardiovascular risk stratification and adequate treatment of arterial hypertension in Switzerland.

APA, Harvard, Vancouver, ISO, and other styles

10

Linde, Anja, Eva Gerdts, Kåre Steinar Tveit, Ester Kringeland, and Helga Midtbø. "Subclinical Cardiac Organ Damage in Patients with Moderate to Severe Psoriasis." Journal of Clinical Medicine 10, no. 11 (May 31, 2021): 2440. http://dx.doi.org/10.3390/jcm10112440.

Full text

Abstract:

We explored the association between subclinical cardiac organ damage (OD) with comorbidities and psoriasis severity in 53 psoriasis patients on infliximab treatment (age 47 ± 15 years, 30% women) and 99 controls without psoriasis (age 47 ± 11 years, 28% women). Cardiac OD was assessed by echocardiography as the presence of increased left ventricular (LV) relative wall thickness (RWT), LV hypertrophy or dilated left atrium. Psoriasis severity was graded using the psoriasis area and severity index (PASI). The prevalence of hypertension was 66% in psoriasis vs. 61% in controls (p = 0.54) and cardiac OD seen in 51 and 73%, respectively (p = 0.007). Psoriasis was associated with a lower prevalence of cardiac OD (odds ratio (OR) 0.32, 95% confidence interval (CI) 0.13–0.77, p = 0.01) independent of age, sex, smoking, body mass index, and hypertension. Among psoriasis patients, hypertension was associated with increased risk of subclinical cardiac OD (OR 6.88, 95% CI 1.32–35.98, p = 0.02) independent of age, sex, and body mass index. PASI at treatment initiation was associated with a higher RWT at follow-up, independent of sex, age, and hypertension (β 0.36, p = 0.006) while no association with current PASI was found. In conclusion, cardiac OD was less prevalent in psoriasis patients on infliximab treatment than controls. Hypertension was the major covariable for subclinical cardiac OD in psoriasis.

APA, Harvard, Vancouver, ISO, and other styles

11

Floria, Mariana, and Daniela Maria Tănase. "Subclinical target organ damage as risk stratification parameter in hypertensive patients." Journal of Clinical Ultrasound 50, no. 6 (July 2022): 769–71. http://dx.doi.org/10.1002/jcu.23249.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Lee, Hyun-Jung, Hack-Lyoung Kim, Jaehoon Chung, Woo-Hyun Lim, Jae-Bin Seo, Sang-Hyun Kim, Joo-Hee Zo, and Myung-A. Kim. "Interaction of Metabolic Health and Obesity on Subclinical Target Organ Damage." Metabolic Syndrome and Related Disorders 16, no. 1 (February 2018): 46–53. http://dx.doi.org/10.1089/met.2017.0078.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Woźnicka-Leśkiewicz, Lucyna, Anna Posadzy-Małaczyńska, and Justyna Marcinkowska. "Gender, subclinical organ damage and cardiovascular risk stratification in hypertensive patients." Current Medical Research and Opinion 35, no. 2 (October 30, 2018): 367–74. http://dx.doi.org/10.1080/03007995.2018.1527304.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Błaszkowska, Magdalena, Anna Shalimova, Bogumił Wolnik, Elżbieta Orłowska-Kunikowska, Beata Graff, Michał Hoffmann, Peter Nilsson, Jacek Wolf, and Krzysztof Narkiewicz. "Subclinical macroangiopathic target organ damage in type 1 diabetes mellitus patients." Blood Pressure 29, no. 6 (May 28, 2020): 344–56. http://dx.doi.org/10.1080/08037051.2020.1770054.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Cuspidi, C. "Is Isolated Systolic Nondipping Pattern Related To Prevalent Subclinical Organ Damage?" American Journal of Hypertension 24, no. 3 (March 1, 2011): 251. http://dx.doi.org/10.1038/ajh.2010.243.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Zuo, J., S. Chu, I. Tan, M. Butlin, J. Zhao, and A. Avolio. "ASSESSMENT OF SUBCLINICAL TARGET ORGAN DAMAGE BY COMPONENTS OF BLOOD PRESSURE." Journal of Hypertension 36, Supplement 1 (June 2018): e72. http://dx.doi.org/10.1097/01.hjh.0000539166.34398.3b.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Khamidullaeva, Gulnoz, Lola Khafizova, and Guzal Abdullaeva. "A13088 Subclinical target organ damage in elderly patients with resistant hypertension." Journal of Hypertension 36 (October 2018): e196. http://dx.doi.org/10.1097/01.hjh.0000548801.41966.1d.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Murashko, Natalia, Anna Bragina, and Valery Podzolkov. "PS 08-81 ENDOTHELIAL MARKERS IN HYPERTENSIVES WITH SUBCLINICAL ORGAN DAMAGE." Journal of Hypertension 34, Supplement 1 (September 2016): e315. http://dx.doi.org/10.1097/01.hjh.0000500775.89012.c1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Kis, É., O. Cseprekál, A. Kerti, T. Horváth, A. J. Szabó, M. Kollai, and G. S. Reusz. "P11.18 DETERMINANTS OF SUBCLINICAL ORGAN DAMAGE IN PAEDIATRIC KIDNEY TRANSPLANT RECIPIENTS." Artery Research 5, no. 4 (2011): 197. http://dx.doi.org/10.1016/j.artres.2011.10.174.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Magurno, Marcello, Daniele Crescibene, Martina Spinali, Velia Cassano, Giuseppe Armentaro, Keti Barbara, Sofia Miceli, Marta L. Hribal, Maria Perticone, and Angela Sciacqua. "Vitamin D and Subclinical Cardiovascular Damage in Essential Hypertension." Endocrines 2, no. 2 (May 31, 2021): 133–41. http://dx.doi.org/10.3390/endocrines2020013.

Full text

Abstract:

Vitamin D deficiency is linked to cardiac dysfunction, vascular remodeling, metabolic syndrome and insulin resistance (IR). The aim of the present study was to evaluate the association between vitamin D levels and cardiovascular (CV) organ damage in a large cohort of newly diagnosed treatment-naïve hypertensive patients, and the role of IR in this context. We enrolled 500 Caucasian individuals, without CV or renal complications. Subjects underwent a complete evaluation and measurements of vitamin D, standard laboratory determinations and instrumental examination, including echocardiography and applanation tonometry. Linear regression analyses were performed to assess the correlation between pulse wave velocity (PWV) and left ventricular mass index (LVMI) with different covariates. PWV was significantly correlated with age (p < 0.0001), LDL cholesterol (p < 0.0001), BMI (p = 0.001), pulse pressure (PP) (p = 0.005) and high sensitivity C-reactive protein (hs-CRP) (p = 0.006), while an inverse correlation was observed with vitamin D levels (p < 0.0001), Matsuda index (p < 0.0001) and estimated glomerular filtration ratio (e-GFR) (p = 0.006). LVMI significantly correlated with PP (p < 0.0001), hs-CRP (p < 0, 0001) and age (p = 0.001), while an inverse relationship was observed with vitamin D levels (p < 0.0001), Matsuda’s insulin sensitivity index (ISI) (p < 0.0001) and e-GFR (p < 0.0001). Vitamin D was the strongest predictor of PWV and LVMI, explaining, respectively, 28.3% and 19.1% of their variation. Our study suggests that low vitamin D might be a biomarker of end-organ damage.

APA, Harvard, Vancouver, ISO, and other styles

21

Peñuela Rodriguez, R. E., J. Lopez, I. Bastidas, R. Hernandez, M. Serrano, W. Zerpa, B. Roman, T. Peñuela, and S. Pereira. "RELATIONSHIP BETWEEN BLOOD PRESSURE AND SUBCLINICAL TARGET ORGAN DAMAGE IN HYPERTENSIVE PATIENTS." Journal of Hypertension 29 (June 2011): e258-e259. http://dx.doi.org/10.1097/00004872-201106001-00725.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Rotar, Oxana P., Maria A. Boyarinova, Ekaterina V. Moguchaia, Ekaterina P. Kolesova, Anastasya M. Erina, Vladislav N. Solntsev, Alexandra O. Konradi, and Eugene V. Shlyakhto. "Subclinical target organ damage in subjects with different components of metabolic syndrome." Clinical and Experimental Hypertension 40, no. 5 (October 25, 2017): 421–26. http://dx.doi.org/10.1080/10641963.2017.1384488.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Diaz, M. A. Prieto, R. Mico Perez, D. Rey Aldana, A. Barquilla Garcia, F. Alonso Moreno, A. Diaz Rodriguez, S. Cinza Sanjurjo, et al. "SUBCLINICAL TARGET ORGAN DAMAGE IN HYPERTENSIVE SUBJECTS INCLUDED IN THE IBERICAN STUDY." Journal of Hypertension 36, Supplement 1 (June 2018): e94. http://dx.doi.org/10.1097/01.hjh.0000539238.28179.39.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Hu, Yueliang, and Junli Zuo. "A18162 The correlation between uric acid level and subclinical target organ damage." Journal of Hypertension 36 (October 2018): e257. http://dx.doi.org/10.1097/01.hjh.0000549051.15572.38.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Lambert, Elisabeth A., Mariam Hachem, Robyn Hemmes, Nora E. Straznicky, Nina Eikelis, Carolina I. Sari, Markus P. Schlaich, Gavin W. Lambert, and John B. Dixon. "Serum uric acid and the relationship with subclinical organ damage in adults." Journal of Hypertension 35, no. 4 (April 2017): 745–52. http://dx.doi.org/10.1097/hjh.0000000000001212.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Perrone-Filardi, Pasquale, Antonio Coca, Maurizio Galderisi, Stefania Paolillo, Francisco Alpendurada, Giovanni de Simone, Erwan Donal, et al. "Noninvasive cardiovascular imaging for evaluating subclinical target organ damage in hypertensive patients." Journal of Hypertension 35, no. 9 (September 2017): 1727–41. http://dx.doi.org/10.1097/hjh.0000000000001396.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Cuspidi, Cesare, Rita Facchetti, Fosca Quarti-Trevano, Raffaella Dell’Oro, Marijana Tadic, Elisa Gherbesi, Guido Grassi, and Giuseppe Mancia. "Clinical correlates and subclinical cardiac organ damage in different extreme dipping patterns." Journal of Hypertension 38, no. 5 (May 2020): 858–63. http://dx.doi.org/10.1097/hjh.0000000000002351.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Leoncini, G., G. Sacchi, M. Ravera, F. Viazzi, E. Ratto, S. Vettoretti, D. Parodi, et al. "Microalbuminuria is an integrated marker of subclinical organ damage in primary hypertension." Journal of Human Hypertension 16, no. 6 (June 2002): 399–404. http://dx.doi.org/10.1038/sj.jhh.1001408.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Peñuela Rodriguez, R. E., J. Lopez, I. Bastidas, R. Hernandez, M. Serrano, W. Zerpa, B. Roman, T. Peñuela, and S. Pereira. "IMPACT OF BLOOD PRESSURE IN DAMAGE SUBCLINICAL TARGET ORGAN IN HYPERTENSIVE PATIENTS." Journal of Hypertension 29 (June 2011): e538-e539. http://dx.doi.org/10.1097/00004872-201106001-01635.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Tasic, I., S. Kostic, D. Djordjevic, M. Lovic, M. Rihter, J. Cvetkovic, S. Andonov, and D. Lovic. "[PP.33.06] SUBCLINICAL ORGAN DAMAGE IN HYPERTENSIVE PATIENTS WITH HIGH CARDIOVASCULAR RISK." Journal of Hypertension 34 (September 2016): e325. http://dx.doi.org/10.1097/01.hjh.0000492297.39994.c1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Lyngbæk, Stig, Thomas Sehestedt, Jacob L. Marott, Tine W. Hansen, Michael H. Olsen, Ove Andersen, Allan Linneberg, et al. "CRP and suPAR are differently related to anthropometry and subclinical organ damage." International Journal of Cardiology 167, no. 3 (August 2013): 781–85. http://dx.doi.org/10.1016/j.ijcard.2012.03.040.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Memaran, Nima, Bianca Borchert‐Mörlins, Bernhard M. W. Schmidt, Rizky I. Sugianto, Hannes Wilke, Ricarda Blöte, Ulrich Baumann, et al. "High Burden of Subclinical Cardiovascular Target Organ Damage After Pediatric Liver Transplantation." Liver Transplantation 25, no. 5 (March 25, 2019): 752–62. http://dx.doi.org/10.1002/lt.25431.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Guşetu, Gabriel, Dana Pop, Cristina Pamfil, Raluca Bǎlaj, Lucian Mureşan, Gabriel Cismaru, Roxana Matuz, Radu Roşu, Dumitru Zdrenghea, and Simona Rednic. "Subclinical myocardial impairment in SLE: insights from novel ultrasound techniques and clinical determinants." Medical Ultrasonography 18, no. 1 (March 1, 2016): 47. http://dx.doi.org/10.11152/mu.2013.2066.181.zdr.

Full text

Abstract:

Aims: Myocardial damage is frequent and often silent in systemic lupus erythematosus (SLE). The aim of the study was to determine the prevalence of myocardial damage by novel ultrasound techniques and to systematically assess the relationship between subclinical cardiac dysfunction and SLE-related clinical parameters. Material and methods: Seventy-five consecutive SLE patients without evidence of cardiac disease and seventy-three controls underwent standard transthoracic echocardiography using classical and novel ultrasound techniques: tissue Doppler imaging and speckle tracking echocardiography. Patient characteristics, cumulative organ damage and laboratory data were retrieved by medical chart review. Results: Within the cohort, 89.3% of the patients were female; mean±SD age and median (IQR) disease duration were 43.2±12.5 years and 8.03(6.3) years, respectively. SLE patients exhibited a significant decrement in endocardial longitudinal strain (-18.4% vs 19.3%, p=0.001) compared with controls. Diastolic dysfunction was detected in 34 (45.3%) of SLE patients. Major determinants of systolic and diastolic dysfunction were hypertension (p=0.023 and p<0.001, respectively), associated antiphospholipid syndrome (APS) (p<0.001 and p<0.001, respectively), cumulative damage accrual (p<0.001 and p=0.003, respectively), and disease duration (p=0.03 and p<0.001, respectively). Notably, anti-Ro antibodies were present in 37% of the SLE patients who had better systolic longitudinal performance. Neither disease activity, nor specific organ involvement, were associated with myocardial impairment. Conclusion: Systolic longitudinal and diastolic performance impairments are frequent findings in SLE patients without overt cardiovascular disease. Cumulative organ damage, disease duration, APS, and hypertension are major determinants for early heart involvement in SLE patients.

APA, Harvard, Vancouver, ISO, and other styles

34

Viazzi, Francesca, Giovanna Leoncini, and Roberto Pontremoli. "Global Cardiovascular Risk Assessment in the Management of Primary Hypertension: The Role of the Kidney." International Journal of Hypertension 2013 (2013): 1–4. http://dx.doi.org/10.1155/2013/542646.

Full text

Abstract:

The knowledge of each patient’s global risk profile is a prerequisite for effective therapeutic strategies in primary hypertension. Detecting the presence of subclinical organ damage at the cardiac, vascular, and renal levels is key for stratifying cardiovascular risk and may also be helpful in choosing antihypertensive agents and in monitoring the effectiveness of treatment. A systematic, in-depth search for subclinical organ damage, however, may be difficult to carry out because of logistic and economic problems related to the high prevalence of hypertension in the population. Renal abnormalities such as microalbuminuria and reduction in glomerular filtration rate have proven to be powerful predictors of cardiovascular and renal outcome. Thanks to their relatively low cost and wide applicability, more widespread use of these tests in the diagnostic workup will help detect subsets of patients at greater risk for whom additional preventive and therapeutic treatment is advisable.

APA, Harvard, Vancouver, ISO, and other styles

35

Woznicka-Leskiewicz, Lucyna, and Anna Posadzy-Malaczynska. "CARDIOVASCULAR RISK AND SUBCLINICAL VASCULAR ORGAN DAMAGE IN PATIENTS WITH AND WITHOUT HYPERTENSION." Journal of Hypertension 40, Suppl 1 (June 2022): e122. http://dx.doi.org/10.1097/01.hjh.0000836488.05154.2d.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Cuspidi, Cesare, Marijana Tadic, Carla Sala, Stefano Carugo, Giuseppe Mancia, and Guido Grassi. "Reverse dipping and subclinical cardiac organ damage: a meta-analysis of echocardiographic studies." Journal of Hypertension 39, no. 8 (March 1, 2021): 1505–12. http://dx.doi.org/10.1097/hjh.0000000000002836.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Ercan, Suleyman, Fatih Goktepe, Bunyamin Kisacik, Yavuz Pehlivan, Ahmet Mesut Onat, Fethi Yavuz, Hayri Alici, and Vedat Davutoğlu. "Subclinical cardiovascular target organ damage manifestations of ankylosing spondylitis in young adult patients." Modern Rheumatology 23, no. 6 (November 2013): 1063–68. http://dx.doi.org/10.3109/s10165-012-0791-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Perrone-Filardi, Pasquale, Antonio Coca, Maurizio Galderisi, Stefania Paolillo, Francisco Alpendurada, Giovanni de Simone, Erwan Donal, et al. "Non-invasive cardiovascular imaging for evaluating subclinical target organ damage in hypertensive patients." European Heart Journal - Cardiovascular Imaging 18, no. 9 (August 7, 2017): 945–60. http://dx.doi.org/10.1093/ehjci/jex094.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Nagy, G., B. Gaszner, É. Lányi, L. Markó, E. Fehér, J. Cseh, T. Kõszegi, et al. "Selective association of endogenous ouabain with subclinical organ damage in treated hypertensive patients." Journal of Human Hypertension 25, no. 2 (March 11, 2010): 122–29. http://dx.doi.org/10.1038/jhh.2010.24.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Sehestedt, T., J. Jeppesen, T. W. Hansen, K. Wachtell, H. Ibsen, C. Torp-Petersen, P. Hildebrandt, and M. H. Olsen. "Risk prediction is improved by adding markers of subclinical organ damage to SCORE." European Heart Journal 31, no. 7 (December 23, 2009): 883–91. http://dx.doi.org/10.1093/eurheartj/ehp546.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Ercan, S., F. Goktepe, B. Kisacik, Y. Pehlivan, A. Onat, F. Yavuz, H. Alici, and V. Davutoglu. "Subclinical cardiovascular target organ damage manifestations of ankylosing spondylitis in young adult patients." European Heart Journal 34, suppl 1 (August 2, 2013): P1599. http://dx.doi.org/10.1093/eurheartj/eht308.p1599.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Androulakis, Emmanuel, Nikolaos Papageorgiou, Eirini Lioudaki, Evaggelos Chatzistamatiou, Effimia Zacharia, Ioannis Kallikazaros, and Dimitris Tousoulis. "Subclinical Organ Damage in White-Coat Hypertension: The Possible Role of Cystatin C." Journal of Clinical Hypertension 19, no. 2 (July 21, 2016): 190–97. http://dx.doi.org/10.1111/jch.12882.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Ling, Zhou, Jiuxiu Lin, Jianan Lin, Zhuo You, Qing Liu, and Dongxia Hong. "A3931 The Relationship between Urinary Magnesium Excretion and Subclinical Hypertensive Target Organ Damage." Journal of Hypertension 36 (October 2018): e152. http://dx.doi.org/10.1097/01.hjh.0000548616.89621.59.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Marcon, Denise, Angela Tagetti, and Cristiano Fava. "Subclinical Organ Damage in Children and Adolescents with Hypertension: Current Guidelines and Beyond." High Blood Pressure & Cardiovascular Prevention 26, no. 5 (October 2019): 361–73. http://dx.doi.org/10.1007/s40292-019-00345-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Tomiyama, Hirofumi, Tomoko Ishizu, Takahide Kohro, Chisa Matsumoto, Yukihito Higashi, Bonpei Takase, Toru Suzuki, et al. "Longitudinal association among endothelial function, arterial stiffness and subclinical organ damage in hypertension." International Journal of Cardiology 253 (February 2018): 161–66. http://dx.doi.org/10.1016/j.ijcard.2017.11.022.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Coutinho, Thais, Stephen T. Turner, and Iftikhar J. Kullo. "Aortic Pulse Wave Velocity Is Associated With Measures of Subclinical Target Organ Damage." JACC: Cardiovascular Imaging 4, no. 7 (July 2011): 754–61. http://dx.doi.org/10.1016/j.jcmg.2011.04.011.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Ashcheulova, Tetiana, Tetiana Ambrosova, Oksana Kochubiei, Oleksii Honchar, and Iryna Sytina. "SUBCLINICAL CARDIAC DAMAGE IN CARDIOPULMONARY POLYMORBIDITY." Inter Collegas 6, no. 2 (August 3, 2019): 68–76. http://dx.doi.org/10.35339/ic.6.2.68-76.

Full text

Abstract:

SUBCLINICAL CARDIAC DAMAGE IN CARDIOPULMONARY POLYMORBIDITY. (review). Part 1. Ashcheulova T., Ambrosova T., Kochubiei O., Honchar O., Sytina I. Hypertension and chronic obstructive pulmonary disease are one of the frequent comorbid conditions in internal medicine and are subject to meaningful cooperation among physicians, cardiologists, and pulmonologists. A combination of chronic obstructive pulmonary disease and hypertension presents certain diagnostic and therapeutic challenges. These conditions share common risk factors, similar clinical presentations and some common parts of pathogenesis. The problem of association between chronic obstructive pulmonary disease and hypertension may be currently discusses both as a simple combination of various clinical entities, and as chronic obstructive pulmonary disease resulting in development of factors contributing to hypertension. One way or another, either a simple combination, or a mutually aggravating syndrome, but we state there is a cardiorespiratory continuum where chronic obstructive pulmonary disease acts as a valid component of hypertension development, and vice versa. Thus, it seems to be relevant to study peculiarities of the structural and functional status of the cardiovascular system and microcirculation, systemic remodeling mechanisms, endothelial dysfunction and inflammation in presence of chronic obstructive pulmonary disease -associated hypertension. Problems of additional cardiovascular risk marker development, treatment efficiency assessment remain topical. Use of electrocardiography and echocardiography with dopplerometry has been an important diagnostic principle of subclinical cardiovascular damage in presence of hypertension and chronic obstructive pulmonary disease comorbidity. Non-invasive imaging methods play a central part in diagnostics of subclinical target organ damage. Wide implementation thereof is based on high diagnostic accuracy, common availability, safety and relatively low price. Key words: hypertension, chronic obstructive pulmonary disease, comorbidity, electrocardiography, echocardiography with dopplerometry Резюме. СУБКЛІНІЧНЕ УРАЖЕННЯ СЕРЦЯ ПРИ КАРДІОПУЛЬМОНАЛЬНІЙ ПОЛІМОРБІДНОСТІ (огляд). Частина 1. Ащеулова Т.В., Амбросова Т.М., Кочубєй О.А., Гончарь О.В., Ситіна І.В. Артеріальна гіпертензія і хронічне обструктивне захворювання легень - одне з частих коморбідних станів в клініці внутрішніх хвороб і є предметом конструктивної взаємодії терапевтів, кардіологів, пульмонологів. Поєднання хронічного обструктивного захворювання легень і артеріальної гіпертензії являє певні труднощі для діагностики і лікування. Ці захворювання мають загальні фактори ризику, схожі клінічні прояви і спільність деяких ланок патогенезу. Таким чином, представляється актуальним дослідження особливостей структурно-функціонального стану серцево-судинної системи і мікроциркуляції, вивчення системних механізмів ремоделювання, ендотеліальної дисфункції та запалення при артеріальній гіпертензії в поєднанні з хронічним обструктивним захворюванням легень. Залишаються актуальними питання розробки додаткових маркерів серцево-судинного ризику, оцінки ефективності проведеного лікування. В останні роки важливими принципами діагностики субклінічного ураження серця і судин при коморбідності хронічного обструктивного захворювання легень і артеріальної гіпертензії є використання електрокардіографії та ехокардіографії з доплерометрією. Неінвазивні методи візуалізації відіграють центральну роль в діагностиці субклінічного ураження органів-мішеней. Їх широке застосування обумовлено високою діагностичної точністю, повсюдною поширеністю, безпекою і відносно низькою вартістю. Ключові слова. Артеріальна гіпертензія, хронічне обструктивне захворювання легень, коморбідность, електрокардіографія, ехокардіографія з доплерометрією. Резюме. СУБКЛИНИЧЕСКОЕ ПОРАЖЕНИЕ СЕРДЦА ПРИ КАРДИОПУЛЬМОНАЛЬНОЙ ПОЛИМОРБИДНОСТИ (обзор). Часть 1. Ащеулова Т.В., Амбросова Т.Н., Кочубей О.А., Гончарь А.В., Сытина И.В. Артериальная гипертензия и хроническое обструктивное заболевание легких - одно из частых коморбидных состояний в клинике внутренних болезней и являются предметом конструктивного взаимодействия терапевтов, кардиологов, пульмонологов. Сочетание хронического обструктивного заболевания легких и артериальной гипертензии представляет определенные трудности для диагностики и лечения. Эти заболевания имеют общие факторы риска, схожие клинические проявления и общность некоторых звеньев патогенеза. Таким образом, представляется актуальным исследование особенностей структурно-функционального состояния сердечно-сосудистой системы и микроциркуляции, изучение системных механизмов ремоделирования, эндотелиальной дисфункции и воспаления при артериальной гипертензии в сочетании с хроническим обструктивным заболеванием легких. Остаются актуальными вопросы разработки дополнительных маркеров сердечно-сосудистого риска, оценки эффективности проводимого лечения. В последние годы важными принципами диагностики субклинического поражения сердца и сосудов при коморбидности хронического обструктивного заболевания легких и артериальной гипертензии является использование электрокардиографии и эхокардиографии с допплерометрией. Неинвазивные методы визуализации играют центральную роль в диагностике субклинического поражения органов-мишеней. Их широкое применение обусловлено высокой диагностической точностью, повсеместной распространенностью, безопасностью и относительно низкой стоимостью. Ключевые слова. Артериальная гипертензия, хроническое обструктивное заболевание легких, коморбидность, электрокардиография, эхокардиография с допплерометрией.

APA, Harvard, Vancouver, ISO, and other styles

48

Scultetus, Anke H., Michelle A. Jefferson, Ashraful Haque, Jordan N. Hubbell, Francoise G. Arnaud, Paula Moon-Massat, Richard M. McCarron, and Debra L. Malone. "Histopathological Evidence of Multiple Organ Damage After Simulated Aeromedical Evacuation in a Swine Acute Lung Injury Model." Military Medicine 185, Supplement_1 (January 2020): 57–66. http://dx.doi.org/10.1093/milmed/usz248.

Full text

Abstract:

ABSTRACT Introduction Rapid aeromedical evacuation (AE) is standard of care in current conflicts. However, not much is known about possible effects of hypobaric conditions. We investigated possible effects of hypobaria on organ damage in a swine model of acute lung injury. Methods Lung injury was induced in anesthetized swine via intravenous oleic acid infusion. After a stabilization phase, animals were subjected to a 4 hour simulated AE at 8000 feet (HYPO). Control animals were kept at normobaria. After euthanasia and necropsy, organ damage was assessed by combined scores for hemorrhage, inflammation, edema, necrosis, and microatelectasis. Results Hemodynamic, neurological, or hematologic measurements were similar prior to transport. Hemodynamic instability became apparent during the last 2 hours of transport in the HYPO group. Histological injury scores in the HYPO group were higher for all organs (lung, kidney, liver, pancreas, and adrenal glands) except the brain, with the largest difference in the lungs (P < 0.001). Conclusions Swine with mild acute lung injury subjected to a 4 hour simulated AE showed more injury to most organs and, in particular, to the lungs compared with ground transport. This may exacerbate otherwise subclinical pathology and, eventually, manifest as abnormalities in gas exchange or possibly end-organ function.

APA, Harvard, Vancouver, ISO, and other styles

49

Koziolova, N. A., A. V. Bushmakina, N. A. Kovalevskaya, and I. M. Shatunova. "Organ-protective effect of fixed-dose combination antihypertensive therapy with eprosartan and hydrochlorothiazide for subclinical and clinical target organ damage in hypertensive patients." Systemic Hypertension 9, no. 4 (December 15, 2012): 28–34. http://dx.doi.org/10.26442/sg28936.

Full text

Abstract:

Aim: to evaluate the efficiency of starting fixed-dose combination therapy with eprosartan and hydrochlorothiazide on the clinical and subclinical parameters of target organ damage in patients with hypertensive disease (HD) irrespective of baseline blood pressure (BP) and cardiovascular risk. Subjects and methods. The study consisted of two parallel substudies. Substudy 1 that screened 3536 workers from industrial enterprises identified 395 (13%) hypertensive patients. Among them, there were 50 (12,7%) untreated patients with HD who had three-component target organ damages: left ventricular hypertrophy, hypertensive nephropathy, peripheral artery lesion. Sixty (15,2%) untreated patients with Stage 1 HD without clinical signs of organ changes were recorded among the same cohort in Substudy 2. In both substudies, Group 1 received a fixed-dose combination of eprosartan mesylate 600 mg once daily and hydrochlorothiazide 12,5 once daily regardless of baseline BP at the onset of the study. Group 2 had monotherapy with enalapril and/or its combination with hydrochlorothiazide depending on the degree of BP elevation and the group of a cardiovascular risk. Results. Starting fixed-dose combination antihypertensive therapy (eprosartan + hydrochlorothiazide) irrespective of baseline BP and cardiovascular risk versus monotherapy with enalapril and/or its free combination with hydrochlorothiazide, which was used in terms of BP level and cardiovascular risk ensured a more significant regression of both clinical and subclinical target organ damages during 6-month therapy according to the changes in left ventricular mass (LVM), LVM index, and tissue inhibitor of type 1 matrix metalloproteinases, microalbuminuria and glomerular filtration rate, intima-media complex thickness during carotid Doppler ultrasound study, and pulse wave velocity in different segments, as evidenced by volumetric sphygmoplethysmography. Conclusions. The use of a fixed-dose combination of eprosartan and hydrochlorothiazide in untreated patients of able-bodied age regardless of baseline BP and cardiovascular risk ensures the regression of target organ damages and the prevention of their development in the absence of organ changes.

APA, Harvard, Vancouver, ISO, and other styles

50

Mychka, Viktoriya Borisovna, Yu V. Zhernakova, and Irina Evgen'evna Chazova. "The improved form perindopril in treatment of arterial hypertension in various clinical situations (PREMIA)." Systemic Hypertension 6, no. 4 (December 15, 2009): 50–53. http://dx.doi.org/10.26442/sg33090.

Full text

Abstract:

The treatment of ACE inhibitors reduce risk of cardiovascular morbidity and mortality. The patients with grade 1-2 hypertension (n=2060) and at least one additional risk factors, subclinical organ damage, established CV or renal disease, diabetes mellitus or metabolic syndrome are recruited in this clinical study. The article presented of study design.

APA, Harvard, Vancouver, ISO, and other styles

Journal articles on the topic 'Subclinical organ damage'

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles